Comparison Of Clinical Efficacy Between Related Mismatched/Haploidentical And HLA-identical Sibling Donor Hematopoietic Stem Cell Transplantation In Treatment Of Hematological Malignancies

Objective: To observe and compare the clinical efficacy of related haploidentical and HLA-identical sibling allo-HSCT in the treatment of hematologic malignancies.Methods: The outcomes of 58 patients with hematologic malignancies undergoing related haploidentical(n=33)or HLA-identical sibling(n=25)hematopoietic cell transplantation performed during the same time period were compared and risk factors related to overall survival(OS)were analyzed.Results:1 Haploidentical and identical sibling cohorts were successfully engrafted.2 The cumulative incidences of gradesⅡ to Ⅳ acute graft-versus-host disease(a GVHD)and grades Ⅲ to Ⅳ a GVHD in the mismatched and matched cohorts were 33.3% versus 24%(P=0.261)and 18.2% versus8%(P=0.611),respectively.3 One-year leukemia-free survival(LFS)and two-year OS in mismatched and matched cohorts were 77% vs 61%(P=0.211)and 72% vs 61%(P=0.118),respectively.4 Multivariate analyses showed that only relapse after allo-HSCT(P=0.033)were risk factors for OS.Conclusion: Related haploidentical transplantation can achieve the similarly therapeutic effects which comparable with HLA-identical sibling transplantation.The incidence of relapse after allo-HSCT was an important factor for the long-term survival.